Christopher Wee, MD, a genitourinary medical oncologist at Cleveland Clinic, discusses available androgen receptor inhibitors for the treatment of patients with nonmetastatic castration-resistant prostate cancer, including apalutamide (Erleada) darolutamide (Nubeqa) and enzalutamide (Xtandi). He also explains what is still needed to optimize the use of these agents in this space.
Olaparib monotherapy shows benefit in HRR+ biochemically recurrent prostate cancer
August 22nd 2024“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.